Publication:
Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsAtasoy, Beste Melek; Dane, Faysal; Kefeli, Aysegul Ucuncu; Caglar, Hale; Cingi, Asim; Turhal, Nazim Serdar; Abacioglu, Ufuk; Yegen, Cumhur
dc.date.accessioned2022-03-12T17:50:42Z
dc.date.available2022-03-12T17:50:42Z
dc.date.issued2011
dc.description.abstractBackground/aims: This study aimed to demonstrate the efficacy and tolerability of low-dose weekly gemcitabine as a radiosensitizer in unresectable pancreatic cancer patients treated with chemoradiotherapy. Methods: Twenty-four histologically confirmed pancreatic carcinoma patients (female/male: 10/14, median age: 60) were evaluated. Seven (29%) patients received gemcitabine either as a single agent or in combination prior to chemoradiotherapy. Concurrent 75 mg/m(2) gemcitabine was infused weekly. Radiotherapy was delivered to the primary tumor and positive lymphatics with 3D-conformal radiotherapy to a total dose of 4500 cGy. Local progression-free survival, distant metastasis-free survival and overall survival were evaluated by Kaplan-Meier method. Results: Median follow-up was 36 weeks. Median local progression-free survival, distant metastasis-free survival and overall survival were 22 weeks (95% confidence interval [CI]: 5-59 weeks), 19 weeks (95%CI: 6.9-31 weeks) and 36 weeks (95%CI: 28-43 weeks), respectively. All patients completed radiotherapy as scheduled. Concurrent gemcitabine was given fully in 58.3% of patients. Gemcitabine was terminated in four (16.6%) patients due to grade 3 neutropenia (n=1), grade 3 nausea/vomiting (n=2) or patient's reluctance (n=1). Patients with local response and stable disease to chemoradiotherapy revealed a median survival of 39 weeks (95%CI: 30-47.9 weeks) compared to 36 weeks (95%CI: 9.7-62.2 weeks) in patients with locally progressive disease (p=0.52). Pain was improved in 50% of patients. Conclusions: Weekly low-dose radiosensitizing gemcitabine is effective and safe in unresectable pancreatic cancer patients.
dc.identifier.doi10.4318/tjg.2011.0158
dc.identifier.issn1300-4948
dc.identifier.pubmed21480113
dc.identifier.urihttps://hdl.handle.net/11424/230205
dc.identifier.wosWOS:000289710100011
dc.language.isoeng
dc.publisherTURKISH SOC GASTROENTEROLOGY
dc.relation.ispartofTURKISH JOURNAL OF GASTROENTEROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChemoradiation
dc.subjectgemcitabine
dc.subjectlow dose
dc.subjectpancreatic cancer
dc.subjectunresectable
dc.subjectTWICE-WEEKLY GEMCITABINE
dc.subjectPHASE-I
dc.subjectCONCURRENT GEMCITABINE
dc.subjectRADIOTHERAPY
dc.subjectRADIATION
dc.subject5-FLUOROURACIL
dc.subjectTHERAPY
dc.subjectADENOCARCINOMA
dc.subjectCARCINOMA
dc.subjectTRIAL
dc.titleConcomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id71a7ce64-459f-4519-bae5-4cdc678c6abd
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.indexed.atTRDIZIN
local.journal.numberofpages5
oaire.citation.endPage64
oaire.citation.issue1
oaire.citation.startPage60
oaire.citation.titleTURKISH JOURNAL OF GASTROENTEROLOGY
oaire.citation.volume22
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Collections

Research Outputs